TP508 (Chrysalin) reverses endothelial dysfunction and increases perfusion and myocardial function in hearts with chronic ischemia

Area of Science:

• Cardiovascular Research
• Vascular Biology
• Regenerative Medicine

Background:

• Endothelial dysfunction (ED) involves impaired nitric oxide (NO) signaling, reduced vasodilation, and inflammation.
• Chronic myocardial ischemia leads to impaired vascular function and reduced heart muscle performance.

Purpose of the Study:

• To evaluate the efficacy of TP508 (Chrysalin), an angiogenic peptide, in treating myocardial revascularization and ED.
• To investigate TP508's effects on NO signaling and endothelial function in a porcine model and human endothelial cells.

Main Methods:

• Utilized a porcine model of chronic myocardial ischemia to assess TP508's impact on perfusion and myocardial wall thickening.
• Measured NO-mediated vasodilation and NO production in ischemic arterioles.
• Examined TP508's effects on endothelial nitric oxide synthase (eNOS) activation, NO production, and eNOS expression in cultured human endothelial cells.

Main Results:

• TP508 increased perfusion in ischemic regions up to 16-fold and doubled myocardial wall thickening compared to placebo.
• TP508 reversed impaired NO-mediated vasodilation and increased NO production in ischemic arterioles.
• In human endothelial cells, TP508 stimulated eNOS activation, increased NO production, and prevented hypoxia-induced eNOS downregulation.

Conclusions:

• TP508 effectively reverses endothelial dysfunction in both a porcine model of ischemic heart disease and cultured human endothelial cells.
• TP508 demonstrates potential therapeutic benefits for myocardial revascularization and treating diseases associated with endothelial dysfunction.